Table 5

Top significantly enriched categories (LogP value < −4) with variants associated with Tourette syndrome

Term IDDescriptionLogPGenes in which variants were foundMAF below, %*
GO:0098609Cell-cell adhesion−13.56CDH23, NLGN1, PTPRT, ROBO2, ADGRL3, CD44, CLSTN2, CNTN4, CTNNA3, FN1, GNAS, LPP, NRXN3, PKHD1, PKP4, PTPRD, SDK1, TENM25.0
GO:0000902Cell morphogenesis−7.93CDH23, EPHB1, NLGN1, ROBO2, SEMA3A, AUTS2, CNTN4, FN1, NCAM1, NRG1, NRXN3, PKHD1, PLXNC1, USH2A5.0
GO:0034329Cell junction assembly−7.75ERBB4, BSN, PKP4, PTPRD, ADGRL3, NRXN1, CDH22, EPB41L3, FN1, CLDN140.1
GO:0034330Cell junction organization−7.70EPHB1, NLGN1, ADGRL3, DLC1, ERBB4, ERC2, FN1, NRG1, PKHD1, PKP4, PTPRD, SDK15.0
GO:0098609Cell-cell adhesion−7.57TENM2, CDH22, CDH23, CNTN4, ROBO2, PTPRD, ADGRL3, CLDN14, PIK3CG, NRXN1, NRXN3, PKP4, FN10.1
R-HSA-9662360Sensory processing of sound by inner hair cells of the cochlea−6.94KCNMA1, EPB41L3, CDH23, CACNA2D2, BSN, SLC17A80.1
GO:0007420Brain development−6.77SATB2, ERBB4, MEIS2, RARB, ROBO2, ALK, PRKG1, CDH22, NDRG2, ADGRL3, EPHB1, ZNF148, SLC17A8, CNTN40.1
GO:0016358Dendrite−6.56CACNA1C, EPHB1, NLGN1, SEMA3A, ANKS1B, CLSTN2, GIGYF2, KCNIP4, MAGI2, SLC4A10, SLC8A1, TENM25.0
GO:0007420Brain development−6.50EPHB1, ROBO2, SEMA3A, MACROD2, ADGRL2, ADGRL3, CNTN4, DLC1, ERBB4, NRG1, PLCB1, RARB, SLC4A10, SLC8A15.0
GO:0008038Neuron recognition−6.44OPCML, ROBO2, NTM, CNTN45.0
GO:0030424Axon−6.41EPHB, ROBO2, SEMA3A, ADGRL3, AUTS2, CNTN4, ERC2, NRG1, SLC4A10, SLC8A1, TENM2, USH2A5.0
GO:0000902Cell morphogenesis−6.06CDH22, CDH23, EPHB1, KLF7, NLGN1, NRXN3, NTN4, PLXNC2, ROBO2, SEMA3A1.0
GO:0098609Cell-cell adhesion−5.90CDH22, CDH23, GNAS, NLGN1, NRXN3, PKP4, PTPRD, ROBO2, TENM21.0
GO:0051963Regulation of synapse assembly−5.90NRXN1, EPHB1, SEMA4A, ROBO2, PTPRD, COLQ0.1
GO:0007626Locomotory behaviour−5.85BTBD9, CDH23, FGF12, GIGYF2, NAV2, NRG1, SLC4A105.0
GO:0005509Calcium ion binding−5.85CDH23, EYS, ADGRL3, CLSTN2, FSTL5, KCNIP4, LTBP1, PLCB1, SLC8A1, STAB2, TENM2, TLL25.0
GO:0040007Growth−5.75EYS, SEMA3A, AUTS2, ERBB4, GIGYF2, GNAS, MAGI2, RARB, SLC4A105.0
GO:0007167Enzyme-linked receptor protein signalling pathway−5.72EPHB1, PTPRT, ANKS1B, ERBB4, FGF12, GIGYF2, LTBP1, MAGI2, NRG1, PLCB1, PTPRD5.0
GO:0007420Brain development−5.65ADGRL2, ALK, CDH22, EPHB1, ERBB4, MACROD2, PRKG1, RARB, ROBO2, SEMA3A, SRGAP2C1.0
GO:0051962Positive regulation of nervous system development−5.47FN1, SEMA4A, MAP3K13, ROBO2, PLXNC1, PTPRD, EPHB1, NRXN10.1
GO:0120035Regulation of plasma membrane bounded cell projection organization−5.36ALK, NLGN1, PLCE1, PLXNC1, PTPRD, ROBO2, SEMA3A, SRGAP2C, TENM21.0
GO:0098858Actin-based cell projection−5.34CDH23, EPHB1, NLGN1, CD44, IQGAP2, TENM2, USH2A5.0
GO:0034330Cell junction organization−5.27CDH22, EPHB1, ERBB4, ERC2, NLGN1, PKP4, PTPRD, SRGAP2C1.0
GO:0050804Modulation of chemical synaptic transmission−5.21BTBD9, EPHB1, NLGN1, CLSTN2, CNTN4, ERC2, PLCB1, PTPRD, SLC4A105.0
GO:0016324Apical plasma membrane−4.89KCNMA1, CD44, FN1, GNAS, PARD3B, PKHD1, SLC4A10, USH2A5.0
GO:0005539Glycosaminoglycan binding−4.89COL25A1, CD44, FN1, HK1, NAV2, STAB25.0
GO:0050885Neuromuscular process controlling balance−4.67NRXN1, RBFOX1, CAMTA1, CDH230.1
GO:0016358Dendrite development−4.16EPHB1, KLF7, PRKG1, SEMA3A1.0
GO:0045932Negative regulation of muscle contraction−4.11PRKG1, KCNMA1, PIK3CDG0.1
WP2118Arrhythmogenic right ventricular cardiomyopathy−4.10CACNA1C, CACNA2D3, CTNNA3, SLC8A15.0
GO:0098858Actin-based cell projection−4.07CDH23, EPHB1, NLGN1, TENM, WWOX1.0
GO:0043408Regulation of MAPK cascade−4.01EPHB1, ERBB4, ALK, MAP3K13, PIK3CG, FN1, NDRG2, NLRP12, PLCE1, MAPKBP10.1
  • MAF = minor allele frequency.

  • * Analyses were performed separately on gene sets with ultra-rare variants (MAF below 0.1%) occurring in at least 2 families, rare variants (MAF below 1%) occurring in at least 3 families, and uncommon variants (MAF below 5%) occurring in at least 4 families.

  • Genes with variants found in all patients in at least n + 1 families, where n is the threshold value selected for a given MAF (i.e., 2 for 0.1%, 3 for 1% and 4 for 5%) threshold.

  • Genes with missense and/or splicing variants.